# A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study

> **NCT01254721** · PHASE4 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 131 (actual)

## Conditions studied

- Acute Bipolar Mania

## Interventions

- **DRUG:** Quetiapine fumarate
- **DRUG:** lithium

## Key facts

- **NCT ID:** NCT01254721
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 131 (ACTUAL)
- **Why stopped:** Difficulty of recruitment.
- **Last updated:** 2014-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01254721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01254721, "A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01254721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*